FDA Approval Of Gilead CAR-T Therapy Will Move The Needle – Seeking Alpha

FDA Approval Of Gilead CAR-T Therapy Will Move The Needle
Seeking Alpha
FDA approves Gilead's first CAR-T therapy Yescarta for patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. The addition of Yescarta to Gilead's pipeline was made possible thanks to the acquisition of …
These 5 Top Stocks Are Moving Late On News: S&P 500 FuturesInvestor’s Business Daily
A cancer treatment that's part of 'a big new field of medicine' just got approvedBusiness Insider
Gilead Gets FDA Approval for New Cancer TherapyWall Street Journal
Quartz –Xconomy –CNBC –San Francisco Business Times
all 44 news articles »